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The concept of plants as factories was launched approximately 5 years ago as a method 
for bio-manufacturing pharmaceuticals, vaccines and industrial enzymes. The advantages 
of the plant system include low-cost manufacturing with limited capital investment for 
growing the biomass, easy scale-up with planting of increased acreage and a system without 
the threat of animal pathogens whether viral, bacterial or prion.
Proof of Concept
The concept has been tested in a number of plant systems at several biotechnology com-
panies, including: ProdiGene (corn; Hood et	al., 003), SemBioSys (safflower; Moloney, 
00), Ventria (rice; Huang, 00), Medicago (alfalfa; Vezina et	al., 00), Biolex (Lemna; 
Gasdaska et	al., 003), Croptech (tobacco; Cramer et	al., 000), Large Scale Biology 
(tobacco; Grill et	al., 00) and Planet Biotechnology (tobacco; Larrick et	al., 00) as 
well as in university research laboratories. The proof of the concept is embodied in these 
research efforts. Plant systems can express proteins at high levels, assemble multimeric 
proteins such as antibodies, and correctly process them, e.g. cleave signal sequences and 
attach glycosylation sequences. Many types of proteins have been expressed in plant 
systems including those ranging in molecular weight from 5,000 daltons (Zhong et	al., 
999) to over 00,000 daltons (Lamphear et	al., 00). These various examples show the 
versatility of the system. The subject of this paper—bovine trypsin produced in transgenic 
maize—illustrates the concept of gene to market, i.e., steps in commercialization of a 
protein product.
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trypsin is a pancreatic serine protease involved in food digestion. Commercially, it is 
produced from bovine refuse from slaughterhouses for applications in cell culture and 
protein processing. Many of the cell cultures are for production of pharmaceutical or 
vaccine proteins, requiring pharmaceutical-grade manufacturing conditions. With the 
existing problems arising from hoof and mouth and mad cow (bovine spongiform en-
cephalopathy) diseases, non-animal sources of trypsin are in high demand. Because bovine 
pancreatic trypsin is now available in maize lines, large-scale production for industrial 
and pharmaceutical applications can be achieved to meet this demand.
Molecular	Biology
In order to express a protein at commercial levels (i.e., as high as possible for the protein 
and plant host), several molecular and cellular parameters must be considered. The use 
of codons that are common to the host plant can enhance the translatability of the mes-
senger rNA. From experience, the leading amino acids appear to be the most critical in 
this regard, presumably because they initiate efficient translation. In the case of bovine 
trypsin, the native Bos	taurus gene was fused in frame with the maize-optimized barley 
alpha-amylase signal sequence (mo-BAASS; rogers, 985), providing twenty-five codon-
optimized amino acids for translation (Woodard et	al., 003), sufficient in this case to 
achieve good expression. Other parameters of interest for high expression of foreign genes 
for protein production include tissue specificity, subcellular localization, germplasm/breed-
ing and protein-specific considerations. For bovine trypsin, tissue specificity was achieved 
through use of the maize globulin- promoter, which is embryo-preferred. Although 
several subcellular locations were tested, the best location for high protein accumulation 
was the apoplast (cell wall) (Hood and Woodard, 00). By far, the greatest challenge 
with expression of bovine trypsin was regeneration of transgenic plants when the gene 
for the active enzyme was used. Therefore, the zymogen form of the protein, trypsinogen, 
was expressed from the holo-gene and transgenic plants, with high expression obtained 
(Woodard et	al., 003). Thus, optimal expression of trypsin in maize was achieved by 
expressing the zymogen form of the gene from the embryo-preferred globulin- promoter, 
and targeting the protein to the apoplast using the maize-optimized barley alpha-amylase 
signal sequence. Using these conditions, the highest first generation seed showed 3.3% 
of total soluble protein (tSP) by enzyme activity (trF, Figure ). 
Variation among transgenic events and among multiple plants from single events, i.e., 
clones, is commonly observed in maize-derived transgenic plants (Hood et	al., 003). 
Because of this, multiple individual lines from multiple events must be screened for the 
protein of interest, to choose the best lines to move forward. However, the maize varieties 
that perform best in tissue culture and transformation are not suitable for field growth. 
Therefore, lines selected for high first-generation expression are planted in field nurseries 
to be improved in agronomic characteristics through a breeding program. Breeding into 
elite inbred germplasm is conducted and resulting lines subsequently selected for high 
expression of the foreign gene of interest as well as for field performance. trypsinogen was 
recovered in bulk seed lots at 58 mg trypsin per kg of seed, or 0.00% of dry weight from 
fifth-generation elite inbred material (Woodard et	al., 003), or approximately double 
the first-generation high single seed.
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Figure. trypsin expression in various transgenic maize lines as a percent of total 
soluble protein (%tSP) from ground seed. trC—zymogen form of trypsin expressed 
from a constitutive promoter and targeted to the cell wall; trD—mature trypsin 
expressed from a constitutive promoter and targeted to the cell wall; trE—zymogen 
form of trypsin expressed from an endosperm-preferred promoter and targeted to 
the amyloplast; trF—zymogen form of trypsin expressed from an embryo-preferred 
promoter and targeted to the cell wall.
Biochemical	Characterization
For commercialization of a product from a new production platform, it is crucial to 
determine the biochemical qualities of the plant-derived protein, including its activity. 
Maize-derived trypsin was mostly active when extracted from ground transgenic seed, and 
exhibited several molecular-weight forms (Figure ). The largest disappeared upon treat-
ment with enterokinase, suggesting it was the trypsinogen form (Woodard et	al., 003). 
When each of the remaining high-molecular-weight forms was subjected to N-terminal 
micro-sequencing, the sequences were the same and matched exactly the sequence of 
the native bovine trypsin, confirming that the N-terminal signal sequence was correctly 
cleaved (Figure ). In addition, these forms were active (Woodard et	al., 003).
For	commercialization	of	a	product	from	a	new	production	
	platform,	it	is	crucial	to	determine	the	biochemical	qualities	of	
the	plant-derived	protein.
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Several methods of analysis were developed to determine the concentration of protein 
in transgenic maize seed. Enzyme-linked immunosorbent assays (ELISAs) provided 
disappointing results in that most transgenic lines exhibited very low concentrations of 
trypsin. However, Western blots suggested that the enzyme was present in substantially 
higher concentrations than the ELISAs had indicated (Figure ). Subsequently, enzyme 
assays were developed to assess the activity of the maize-derived enzyme, and the results 
agreed closely with the Western blots, suggesting that the trypsin was digesting protein 
components in the ELISA.
Physical parameters of maize-derived trypsin matched the native protein in all instances 
with the exception of the molecular weight of extracted protein (table ; Figure ). The 
differences in molecular weight were apparently due to O-linked glycosylation sequences 
on the maize-derived protein, and when removed by chemical means, the proteins had 
the same apparent molecular weight (Woodard et	al., 003). Specific activity, pH opti-
mum, Km and Vmax values were not significantly different between the two sources of 
enzyme (table ).
Figure . trypsin characterization. Western blot of maize-derived trypsin. Bt = Bos 
taurus; Zm=Zea	mays; tn=trypsin; tg=trypsinogen. Numbers to the left indicate mi-
gration of molecular-weight markers. Box to the right indicates N-terminal sequence 
of three active forms of maize-derived trypsin and values for trypsin concentration 
from several averaged samples using three assay methods.
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Product Development
A product is not just the protein of interest in a transgenic plant. It is the protein of interest 
utilized in a certain market application, each of which creates a different product. Thus, 
many products can be developed from one protein-expressing plant line. Development of 
crop-derived proteins into real-world industrial or pharmaceutical products comprises a 
number of activities including applications testing and market development, a freedom-
to-operate assessment, patent protection, a safety assessment, breeding into elite material 
for best field performance, small-scale production and formulation requirements. All 
aspects must be developed in a way that meets cost targets. 
Applications for trypsin include digestive aids, detergent additives, processing of 
commercial proteins, commercial cell culture, an active pharmaceutical product, eye-
care products and leather processing. The major question for maize-derived trypsin is 
whether it can substitute for the bovine product in these applications. In several trials, 
the maize-derived enzyme functioned equally as well as the bovine counterpart (S.L. 
Woodard, unpublished). 
Market development for maize-derived replacement products for existing markets 
mainly comprises focus on the advantages of a plant-derived protein. First and foremost, 
the plant-derived enzyme can be utilized in markets that are sensitive to the source of 
the product and the associated need to avoid animal pathogens. This is particularly true 
for cell culture, pharmaceutical use, and commercial reagent proteins that are utilized 
to process pharmaceutical proteins. A second advantage is low cost for markets not 
sensitive to these cleanliness issues. A third advantage is the ability to scale-up for large 
market applications for which microbial production systems are less appropriate because 
of capital requirements.
Freedom to operate (FtO) is a complex issue for plant-derived products—“can I 
practice my processes and produce my product without running afoul of others’ patents?” 
Table 1. biochemical characTerizaTion of bovine TrypSin from maize 
and naTive SourceS.
 Parameter Maize-derived trypsin Bovine trypsin
 Molecular weight (MALDI tOF) 3,97 daltons 3,30 daltons
 Specific activity 75 U/mg protein  U/mg protein
 Glycosylation O-linked none
 Km .7 mM 3. mM
 Vmax 0.9 0.30
 pH optimum 8. 8.7
Development	of	crop-derived	proteins	into	real-world	industrial	
or	pharmaceutical	products	comprises	a	number	of	activities.
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(Sweeney, 00). Determining FtO is a process that requires constant diligence and 
many licenses, particularly in competitive areas of research and technology development. 
Whenever new materials are brought into an entity or the entity’s materials are shared with 
others, FtO issues can be raised. And, obviously, not only materials are at stake. Often 
processes for creating products are patented; for example, transformation protocols and 
breeding strategies are equally subject to licensing requirements. Diligence in this area 
with company or university attorneys is critical to success.
Patent protection is essential to successful market entry, particularly if the technology 
or product can be manufactured by other firms, or the technology of interest makes a 
product possible when it previously was not available. Proteases in general are difficult 
to produce in xenogenic systems because of their detrimental effect on native protein 
content. In 000, ProdiGene was issued a broad-based patent (USP # ,087,558) describ-
ing the production of proteases in transgenic plants, claiming expression of any protease 
in any transgenic plant, where the protease is expressed in the zymogen form. This is a 
fundamental technology, because recovery of transgenic plants expressing high levels of 
active proteases is nearly impossible unless zymogens are expressed in seed.
Maize transgenic events are generated in material that has poor agronomic character-
istics. Thus, breeding into elite germplasm is essential for field performance that meets 
production requirements. This process takes from  to  years depending on the need 
to reach yield parity for profit margin and whether year-round nurseries are used for 
the acceleration of generations. If yield parity with commodity corn is required to meet 
production-cost requirements, then five to seven generations of crossing into elite inbred 
germplasm is required with two additional selfed generations before making a hybrid (D. 
Delaney, personal communication). The germplasm of choice depends upon the field 
production location, and if more than one zone will be required for crop production, 
more inbreds will be required for the breeding program. A minimum of two generations 
per year can be accomplished in midwestern US summer nurseries alternating with Puerto 
rican (or other Caribbean island) winter nurseries. However, with year-round nurseries 
in Hawaii, .5 to 3 generations per year can be accomplished. If the cost of the product 
and immediacy of the market opportunity warrant, the higher cost of year-round nurseries 
can often be justified, cutting significantly the time involved in development of genetic 
production material.
One of the major goals of the breeding program, in addition to lines with adequate field 
performance, is generating lines with commercial levels of expression of the gene of interest. 
Minimum concentrations of protein in corn meal for different types of products—purified 
pharmaceuticals, orally delivered vaccines, industrial enzymes or cellulases—are shown in 
table  (J. Howard, personal communication). For the trypZean™ product, the minimum 
concentration of trypsin in dry seed material should be 0.0–0.% to meet production-
Breeding	into	elite	germplasm	is	essential	for	field	performance	
that	meets	production	requirements.
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cost targets because in this lyophilized powder formulation it is considered a cell-culture 
reagent protein, thus falling between the purified pharmaceutical and industrial enzyme 
application requirements. As stated above, the concentration of trypsin in fifth-genera-
tion breeding material is approximately 0.00% of dry weight, somewhat lower than 
what will be required for a profitable product. However, because breeding and selection 
can generate material that expresses the recombinant protein at ten to a hundred times 
higher than the initial transformant (Hood et	al., 003), continued breeding and selection 
should yield lines with the required expression level.
During the breeding program, small-scale production can be accomplished from hybrid 
seed samples taken from the breeding material and subsequently grown in field plots. two 
goals can be achieved with this material: assessment of the improvement in agronomic 
character of interim hybrids and small-scale extraction/purification of the protein of 
interest for applications trials. These two assessments are critical to timely identification 
of potential problems in the product-development timeline.
The final formulation of the protein product is entirely a requirement of the applica-
tion. For maize-derived trypsin, the product trypZean™ is a lyophilized powder bottled 
for laboratory use as a cell-culture-dissociation reagent. For other uses, the formulation 
might be ) a stabilized liquid, ) ground, unextracted corn meal, or 3) ground, defatted 
corn-germ meal. In all cases, the cost of formulation must be compatible with the sale 
price of the product.
A product safety assessment includes understanding the hazard of the specific protein 
of interest alone or within the plant material. Once the inherent hazard of the protein has 
been quantified, one can determine the risk associated with various levels of exposure to 
it (risk is proportional to hazard multiplied by exposure) (Howard and Donnelly, 00). 
While this assessment will not satisfy all regulatory-compliance issues, it is a required 
component and will assist in establishing confinement measures for regulatory compliance. 
The field of product safety versus regulatory compliance is in flux and requires constant 
attention to remain apprised of status.
Production
Production of crop-derived proteins requires scale-up of activities similar to those described 
in product development. Additionally, it requires a plan for compliance with US Depart-
ment of Agriculture (USDA) and Food and Drug Administration (FDA) regulations, or 
Table 2. minimum concenTraTionS of foreign proTein in geneTically 
modified producTion maTerial for coST-effecTive producTion.
 Product Application requirement Minimum concentration
 For oral delivery of vaccines ~ mg required for dose 0.% DW
 For purified pharmaceuticals Less expression-sensitive 0.0% DW
 For industrial enzymes <$00/kg production cost >0.% DW
 For cellulase for ethanol 0 g/gallon ethanol >3% DW
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those of other agencies depending upon the product. The steps involved in production, 
growing, harvesting and associated activities, processing, and extraction/purification are 
outlined in table 3.
Corn containing bovine trypsin—or any transgene for protein production—should be 
grown in areas where crop development is efficient and cost-effective, i.e., the midwestern 
corn-belt. Otherwise much of the advantage of using a commodity crop for low-cost 
production is lost (Howard and Hood, 005). The total acreage required is a product 
of seed yield and recombinant protein concentration in the seed. For example, trypsin 
in the fifth generation was at a concentration of 0.00% of whole-seed dry weight. If 
the corn produced 50 bushels per acre, equal to 3,750 kg of grain per acre, the yield of 
trypsin per acre would be 5 g. If the desired production amount is 0 kg for market 
entry, approximately 5 acres would be required. Confinement to meet USDA regulations 
requires a buffer zone of  mile wide surrounding the field, plus other measures such as 
delayed planting compared to other corn-production fields in the area. Male sterility can 
also be utilized, but the trypsin material is not male sterile.
Table 3. producTion STepS and parameTerS To be conSidered during 
producTion of TrypSin from TranSgenic maize.
 Production step Considerations for trypsin in corn
 Growing Biological requirements for corn,
  seasonal and geographic limitations,
  recombinant protein yield,
  confinement regulations
 Harvesting/ transportation/Storage Mechanical issues, time,
  temperature sensitivity, cost,
  protein stability in tissue
 tissue processing Stability in tissue,
  potential for enrichment,
  small batches, whole seed,
  large batches, dry mill for germ,
  extract oil 
 Extraction/Purification Protein stability,
  biomass quantity versus yield,
  cGMP for pharma applications,
  formulations
Corn	containing	bovine	trypsin—or	any	transgene	for	protein	
production—should	be	grown	in	areas	where	crop	development	is	
efficient	and	cost-effective.
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Figure 3. relative contribution of maize kernel tissues to total seed weight. Numbers to 
the right compare the concentration of recombinant protein in each tissue based on a 
whole-seed expression level of 0.0% dry weight.
Corn seed is harvested mechanically when the moisture content is below approxi-
mately 0%. Shelling is accomplished best when moisture content is below 5%. Field 
drying is the most cost-effective method, but harvest should occur before a severe frost, 
and if necessary the ears can be mechanically dried after collection. Current regulations 
require dedicated equipment for non-food products from genetically modified crops. 
Once the grain is harvested, dried and shelled, it can be stored for months to years. Most 
foreign proteins in genetically modified seed are quite stable in dried grain (Hood et	al., 
997; Hood et	al., 003; Lamphear, 00), and trypsin is no exception (S.L. Woodard, 
unpublished).
One of the advantages of grain crops for bioproducts is the ability to partition proteins 
into specific tissue sinks (Figure 3). trypsin is expressed largely in the embryo of the kernel, 
with much less present in the endosperm. Because the embryo represents only 0% of the 
dry weight of the kernel, separating it from the endosperm effectively concentrates the 
protein ten-fold on a dry-weight basis. tissue separation can be accomplished with either 
dry-milling or wet-milling operations. The recombinant protein must be compatible with 
the temperatures used in either process, and the solutions used in the wet-milling process. 
In the future, oil will be extracted and sold as a co-product when the germ is isolated, 
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particularly if the transgenic product is deregulated. tissue processing is not usually cost 
effective at less than a million bushels. Therefore, at 7,500 bushels from 5 acres of corn, 
whole-seed grinding and subsequent extraction will be a more cost-effective production 
method than seed fractionation for trypsin.
Currently, trypsin is a purified, lyophilized product, trypZean™ (Sigma Chemical Co., 
St. Louis, MO). Thus, extraction and purification are necessary for its production and 
sale. Extraction buffers have been developed to maximize trypsin recovery and minimize 
extraction of native corn proteins. Subsequent purification protocols maximize recovery 
and stability balanced with purity. In many cases, 50% or less of the protein is recovered 
from the starting material, indicating that twice the acreage estimated above would be 
needed for production.
A	lack	of	public	acceptance	is	the	major	barrier	today	to	
	producing	biopharmaceutical	or	bioindustrial	products	in	plants.
Public Acceptance and Sale
A lack of public acceptance is the major barrier today to producing biopharmaceutical 
or bioindustrial products in plants. response to this public distrust has driven current 
regulations to be quite restrictive. The scientific community and the regulatory agencies are 
striving to gather substantive safety data to support regulations that are based on scientific 
principles and will protect the public as well as allow this new industry to develop. This 
topic has been discussed in detail in recent reviews on bioproduction and product safety 
(Howard and Donnelly, 00; Howard and Hood, 005). The critical asset for general 
public acceptance is whether the consumer sees benefits and whether these perceived 
benefits outweigh costs and risks. When products with obvious benefits are available to 
the consumer, public acceptance, science-based regulations and sales will fall into place.
references
Cramer CL et	al. (000) transgenic plants for therapeutic proteins: Linking upstream 
and downstream strategies. Current topics in Microbiology and Immunology 0 
95–8.
Gasdaska Jr et	al. (003) Advantages of therapeutic protein production in the aquatic 
plant Lemna. Bioprocessing Journal  9–5.
Grill LK et	al. (00) Viral vector expression of foreign proteins in plants. In: Plants 
as Factories for Protein Production (Hood EE Howard JA eds.). Dordrecht: Kluwer 
Academic Publishers, pp. 3 – .
Hood EE et	al. (997) Commercial production of avidin from transgenic maize: Char-
acterization of transformant, production, processing, extraction and purification. 
Molecular Breeding 3 9–30.
Hood EE et	al. (003) Criteria for high-level expression of a fungal laccase gene in trans-
genic maize. Plant Biotechnology Journal  9–0.
57
Hood EE Woodard SL (00) Industrial proteins produced from transgenic plants. In: 
Plants as Factories for Protein Production (Hood EE Howard JA eds.). Dordrecht: 
Kluwer Academic Publishers, pp. 9–35.
Howard JA Donnelly KC (00) A quantitative safety assessment model for transgenic 
protein products produced in agricultural crops. Journal of Agricultural and Environ-
mental Ethics 7 55–558.
Howard JA Hood E (005) Bioindustrial and biopharmaceutical products produced in 
plants. Advances in Agronomy 85 8–.
Huang N (00) High-level protein expression system uses self-pollinating crops as hosts. 
BioProcessing International  5–59.
Lamphear BJ et	al. 00 A corn-based delivery system for animal vaccines: an oral trans-
missible gastroenteritis virus vaccine boosts lactogenic immunity in swine. Vaccine 
 0–.
Larrick JW et	al. (00) Production of secretory IgA antibodies in plants. Biomolecular 
Engineering 8 87–9. 
Moloney MM (00) Plant molecular farming: Using oleosin partitioning technology 
in oilseeds. In: Plants as Factories for Protein Production (Hood EE Howard JA eds.). 
Dordrecht: Kluwer Academic Publishers, pp 55–75.
rogers JC (985) two barley alpha-amylase gene families are regulated differently in 
aleurone cells. Journal of Biological Chemistry 0 373–3738.
Sweeney PA 00 A warehouse of ideas: Developing and using intellectual property. In: 
Plants as Factories for Protein Production (Hood EE Howard JA eds.). Dordrecht: 
Kluwer Academic Publishers, pp.8–0.
Vezina LP et	al. (00) Alfalfa, a perennial source of recombinant proteins. In: Plants 
as Factories for Protein Production (Hood EE Howard JA eds.). Dordrecht: Kluwer 
Academic Publishers, pp. 7–5.
Woodard SL et	al. (003) Maize (Zea	mays)-derived bovine trypsin: characterization of 
the first large-scale, commercial protein product from transgenic plants. Biotechnology 
and Applied Biochemistry 38 3–30.
Zhong GY et	al. (999) Commercial production of aprotinin in transgenic maize seeds. 
Molecular Breeding 5 35–35.
Hood, Woodard
58 Agricultural Biotechnology: Beyond Food and Energy to Health and the Environment
Elizabeth Hood has had twenty-five years 
experience in biology. She is currently associ-
ate vice chancellor for research and technology 
transfer at Arkansas State University. She was a 
program director in molecular and cellular bio-
sciences at the National Science Foundation for 
the 003–00 academic year. Dr. Hood was a 
leader in forming one of the world’s foremost 
transgenic plant-research groups at ProdiGene, 
a biotechnology start-up company. Previous 
to ProdiGene, she was director of the cell biology group for plant production of 
therapeutic proteins at Pioneer Hi-Bred International.
Hood has over seventy publications and patents to her credit and she has been 
an advisor for graduate programs at several universities. Currently she holds 
adjunct positions at texas A&M University in the Department of Biochemistry 
and Biophysics and in the Molecular and Environmental Plant Sciences program. 
Her previous positions were with Utah State University, the Swedish University 
of Agricultural Sciences, Washington University in St. Louis and Oklahoma State 
University. She earned her PhD in plant biology from Washington University and 
an MS in botany from Oklahoma State. Her research interests are in the areas of 
renewable resources, foreign-gene expression in transgenic plants, plant cell-wall 
structure and function, and plant cell biology and protein targeting.
